These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21147401)

  • 21. CONSORT and QUOROM guidelines for reporting randomized clinical trials and systematic reviews.
    Turpin DL
    Am J Orthod Dentofacial Orthop; 2005 Dec; 128(6):681-5; discussion 686. PubMed ID: 16360902
    [No Abstract]   [Full Text] [Related]  

  • 22. The PRISMA extension for network meta-analysis: bringing clarity and guidance to the reporting of systematic reviews incorporating network meta-analyses.
    Cornell JE
    Ann Intern Med; 2015 Jun; 162(11):797-8. PubMed ID: 26030637
    [No Abstract]   [Full Text] [Related]  

  • 23. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher D; Liberati A; Tetzlaff J; Altman DG;
    J Clin Epidemiol; 2009 Oct; 62(10):1006-12. PubMed ID: 19631508
    [No Abstract]   [Full Text] [Related]  

  • 24. [PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses].
    Urrútia G; Bonfill X
    Med Clin (Barc); 2010 Oct; 135(11):507-11. PubMed ID: 20206945
    [No Abstract]   [Full Text] [Related]  

  • 25. Reporting guidelines: CONSORT, PRISMA, and SQUIRE.
    Foster RL
    J Spec Pediatr Nurs; 2012 Jan; 17(1):1-2. PubMed ID: 22188266
    [No Abstract]   [Full Text] [Related]  

  • 26. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher D; Liberati A; Tetzlaff J; Altman DG;
    Ann Intern Med; 2009 Aug; 151(4):264-9, W64. PubMed ID: 19622511
    [No Abstract]   [Full Text] [Related]  

  • 27. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher D; Liberati A; Tetzlaff J; Altman DG;
    BMJ; 2009 Jul; 339():b2535. PubMed ID: 19622551
    [No Abstract]   [Full Text] [Related]  

  • 28. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher D; Liberati A; Tetzlaff J; Altman DG;
    PLoS Med; 2009 Jul; 6(7):e1000097. PubMed ID: 19621072
    [No Abstract]   [Full Text] [Related]  

  • 29. Improving the quality of the evidence - The necessity to lead by example.
    Simons M; Busch K; Avolio A; Kiat H; Davidson A
    J Clin Neurosci; 2017 Dec; 46():165-166. PubMed ID: 28974392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The PRISMA statement extension for systematic reviews incorporating network meta-analysis: PRISMA-NMA].
    Hutton B; Catalá-López F; Moher D
    Med Clin (Barc); 2016 Sep; 147(6):262-6. PubMed ID: 27040178
    [No Abstract]   [Full Text] [Related]  

  • 31. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Moher D; Liberati A; Tetzlaff J; Altman DG;
    Int J Surg; 2010; 8(5):336-41. PubMed ID: 20171303
    [No Abstract]   [Full Text] [Related]  

  • 32. The PRISMA Extension Statement.
    Tian JH; Ge L; Li L
    Ann Intern Med; 2015 Oct; 163(7):566. PubMed ID: 26436628
    [No Abstract]   [Full Text] [Related]  

  • 33. The PRISMA Extension Statement.
    Hutton B; Moher D; Cameron C
    Ann Intern Med; 2015 Oct; 163(7):566-7. PubMed ID: 26436629
    [No Abstract]   [Full Text] [Related]  

  • 34. The quality of reports of critical care meta-analyses in the Cochrane Database of Systematic Reviews: an independent appraisal.
    Delaney A; Bagshaw SM; Ferland A; Laupland K; Manns B; Doig C
    Crit Care Med; 2007 Feb; 35(2):589-94. PubMed ID: 17205029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primer: strengths and weaknesses of meta-analysis.
    Finckh A; Tramèr MR
    Nat Clin Pract Rheumatol; 2008 Mar; 4(3):146-52. PubMed ID: 18227829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodologic issues in systematic reviews and meta-analyses.
    Montori VM; Swiontkowski MF; Cook DJ
    Clin Orthop Relat Res; 2003 Aug; (413):43-54. PubMed ID: 12897595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
    Moher D; Shamseer L; Clarke M; Ghersi D; Liberati A; Petticrew M; Shekelle P; Stewart LA;
    Syst Rev; 2015 Jan; 4(1):1. PubMed ID: 25554246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PRISMA statement.
    Moher D; Altman DG; Liberati A; Tetzlaff J
    Epidemiology; 2011 Jan; 22(1):128; author reply 128. PubMed ID: 21150360
    [No Abstract]   [Full Text] [Related]  

  • 39. Methodological concerns and quality appraisal of contemporary systematic reviews and meta-analyses in pediatric urology.
    Braga LH; Pemberton J; Demaria J; Lorenzo AJ
    J Urol; 2011 Jul; 186(1):266-71. PubMed ID: 21600615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic reviews and meta-analyses "For Dummies".
    Biondi-Zoccai GG; Abbate A; Sheiban I
    EuroIntervention; 2009 Aug; 5(3):289-91. PubMed ID: 19736151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.